

29 June 2026

genedrive plc
("genedrive" or the "Company")

CYP2C19 Product Development Collaboration agreement with Thermo Fisher Scientific Inc.

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce a collaboration agreement with Thermo Fisher Scientific Inc. enabling genedrive to develop a CYP2C19 pharmacogenetic in vitro diagnostic ("IVD") test for deployment on Thermo Fisher Scientific's QuantStudio™ 5 Dx real-time PCR laboratory platform (the Genedrive® CYP2C19 HT Kit).

The Genedrive® CYP2C19 HT Kit is designed for centralised, high-throughput laboratory testing, addressing a different market segment to the Company's rapid Genedrive® CYP2C19 ID Kit, which targets near-patient settings. Together, the two products position genedrive to serve both decentralised and laboratory-based CYP2C19 pharmacogenetic testing pathways. The Genedrive® CYP2C19 HT Kit is on track for UKCA certification around the end of the 2026 calendar year, initially targeting the UK NHS genomic laboratory market.

The Genedrive® CYP2C19 HT kit targets the same clinically relevant allele panel (*2, *3, *4, *8, *17 and *35) to maximise ethnic inclusivity and is configured as a multiplexed PCR reaction, enabling high sample throughput per run. It is supplied in a lyophilised, ambient temperature-stable format and operates directly from blood without nucleic acid extraction, reducing workflow complexity, hands-on time, and consumable use in high-throughput laboratory environments, maximising sample throughput and minimising hands-on time, processing steps, and consumable use.

There are approximately 100,000 new stroke patients annually in the UK, with approximately 94 million people living with the effects of stroke globally, at a cost of \$890 billion per year. In the US each year, there are approximately 690,000 ischaemic strokes, 240,000 TIAs, and 550,000 percutaneous coronary interventions ("PCI") in coronary artery disease.

CYP2C19 pharmacogenetic testing is recommended by the UK National Institute for Health and Care Excellence ("NICE") (<https://www.nice.org.uk/guidance/htg724>) to guide the use of the antiplatelet drug clopidogrel following ischaemic stroke ("IS") or transient ischaemic attack ("TIA"). NICE recommends laboratory-based CYP2C19 genotype testing and the use of the Genedrive® CYP2C19 ID Kit for rapid point-of-care testing when laboratory-based testing is not available. The American Heart Association supports CYP2C19 genotyping to guide antiplatelet therapies in coronary artery disease, peripheral artery disease, and stroke, and CYP2C19 genotyping.

Dr Gino Miele, CEO of genedrive plc, said: *"This collaboration expands our CYP2C19 offering into the high-throughput laboratory diagnostics market, complementing our established point-of-care solution. In addition to access to industry standard chemistries, this collaboration with Thermo Fisher Scientific will enable us to leverage a large global installed base of laboratory diagnostic PCR platforms, accelerating access to a significant new market segment while strengthening our existing pharmacogenetic testing portfolio."*

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO	https://investors.genedrive.com/s/e0025c
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel	
5654 & Company (Media & Investor Relations)	genedrive@5654.co.uk
Matthew Neal	+44 (0)7917 800 011
Melissa Gardiner	+44 (0)7757 697357

Subscribe to our news alert service: <https://investors.genedrive.com/s/efea03>

About genedrive plc (<http://www.genedrive.com>).

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

The QuantStudio 5 Dx is For In Vitro Diagnostic Use.

The Genedrive® CYP2C19 HT Kit is For performance evaluation only.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGRFPMTMTMTBTF